These results come from the Phase I and II trials of therapy, where researchers assess its safety and effectiveness against a given condition.
Key findings of Report
- Lower costs: Cost is 1/20th of similar global therapies.
- Side Effects & Risks: Most common side effects reported by study were anemia in 61% participants, low platelet count in 65% patients, low count of white blood cells etc.
About CAR (Chimeric Antigen Receptor) T-Cell Therapy
- It modifies immune cells, specifically T-cells, by turning them into potent cancer fighters known as CAR-T cells.
- T-cells are special cells (types of white blood cells) whose primary function is cytotoxic, meaning killing other cells.
- This treatment is designed for specific types of blood cancer and is given to patients whose cancer has either relapsed or not responded to first-line treatment.
Benefits of CAR T-Cell therapy
- Short treatment duration: Unlike aggressive chemotherapy or stem cell transplants, it allows for a faster recovery.
- A "Living Drug" with Sustained Benefits: CAR T-cells persist in the body, offering long-term protection against cancer relapse.
Challenges
- Cytokine Release Syndrome: Over activation of immune cells leads to high fever, organ failure etc.
- Neurotoxicity: Ranges from confusion and seizures to cerebral edema and coma.
- Antigen Escape: Tumors develop resistance by losing antigen targeted by CAR-T cells.
